N/A
Completed N=2,140
Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
Methicillin-resistant Staphylococcus Aureus
Source: ClinicalTrials.gov NCT01209234 ↗
Enrolled (actual)
2,140
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026
Summary
This randomized controlled trial will compare strategies to reduce the risk of methicillin-resistant Staphylococcus aureus (MRSA) infection and re-hospitalization in MRSA carriers. This trial will provide critical answers about the role of decolonization versus standard-of-care education in preventing MRSA infections in the large group of high risk MRSA-positive patients being discharged from hospitals. Findings could potentially impact best practice for the 1.8 million MRSA carriers who are discharged from US hospitals each year.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to MRSA Infection |
67; 98; 68; 98 | 0.026 sig |
| SECONDARY Time to All-cause Infection (Steering Committee Modified Oct 2011) |
207; 252; 246; 298 | 0.061 |
Eligibility Criteria
Inclusion Criteria
- 1) At least 18 years old
- 2) Have had a positive culture (a type of test) for MRSA during recent hospital admission or within the 30 days prior to admission or following discharge
- 3) Able to give consent or have a primary caregiver provide consent
- 4) Able to bathe or shower or have this consistently performed by a willing caregiver
Exclusion Criteria
- 1) Known allergies to chlorhexidine or mupirocin
Data sourced from ClinicalTrials.gov (NCT01209234). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.